MorphoSys Strengthens Patent Position on anti-CD19 Cancer Program MOR208
MARTINSRIED / MUNICH, Germany, Oct. 22, 2013 (GLOBE NEWSWIRE) --
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced
today that the US Patent and Trademark Office (USPTO) has granted a patent
covering the Company's cancer compound MOR208. The new patent (US 8,524,867)
covers the antibody's protein sequence as well as pharmaceutical compositions
comprising the same. The new patent has a scheduled expiry date in 2029, not
including any potential patent office or regulatory extensions, and is licensed
to MorphoSys AG from Xencor, Inc.
Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG, commented: "We are
very optimistic about the prospects of MOR208 and are building a rich
scientific, medical and commercial package around this program, in order to lay
the groundwork for future commercialization."
MOR208 is a humanized monoclonal antibody that targets the antigen CD19 for
treatment of B cell malignancies and autoimmune diseases. The antibody has been
engineered to possess significantly enhanced antibody-dependent cell-mediated
cytotoxicity (ADCC), thus improving a key mechanism for tumor cell killing and
offering potential for enhanced efficacy compared to traditional antibodies for
the treatment of cancer.
MOR208 has shown in a Phase 1/2a trial encouraging signs of preliminary anti-
tumor activity and an acceptable safety and tolerability profile in patients
with high-risk, heavily pretreated chronic lymphocytic leukemia (CLL) or small
lymphocytic lymphoma (SLL). The study results showed an overall response rate of
29.6% (according to IWCLL 2008 criteria) based on the safety population of the
trial (n=27). MorphoSys is conducting Phase 2 clinical trials of MOR208 in
patients with non-Hodgkin's lymphoma (NHL) and B-cell acute lymphoblastic
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 80 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®)
and Ylanthia(®) and 100 billion high potentials(®) are registered trademarks of
Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
Media Release (PDF): http://hugin.info/130295/R/1737008/582252.pdf
Press spacebar to pause and continue. Press esc to stop.